BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37106286)

  • 61. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line.
    Lee SJ; Li GG; Kim ST; Hong ME; Jang J; Yoon N; Ahn SM; Murphy D; Christiansen J; Wei G; Hornby Z; Lee DW; Park JO; Park YS; Lim HY; Hong SN; Kim SH; Kang WK; Park K; Park WY; Kim KM; Lee J
    Oncotarget; 2015 Nov; 6(36):39028-35. PubMed ID: 26472021
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Chromosomal imbalances detected in NTRK-rearranged sarcomas by the use of comparative genomic hybridisation.
    Vargas AC; Ardakani NM; Wong DD; Maclean FM; Kattampallil J; Boyle R; Santos L; Gill AJ
    Histopathology; 2021 Jun; 78(7):932-942. PubMed ID: 33128780
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Comparison of the methods for detecting NTRK gene fusion variations in papillary thyroid carcinoma].
    Jiang YY; Chen H; Xu BL; Wang S
    Zhonghua Bing Li Xue Za Zhi; 2022 Aug; 51(8):726-732. PubMed ID: 35922162
    [No Abstract]   [Full Text] [Related]  

  • 64. [Secretory carcinoma of salivary gland: a clinicopathological and prognostic analysis of twelve cases].
    Cao YS; Lyu XQ
    Zhonghua Bing Li Xue Za Zhi; 2021 Aug; 50(8):899-903. PubMed ID: 34344073
    [No Abstract]   [Full Text] [Related]  

  • 65. GISTs with
    Cao Z; Li J; Sun L; Xu Z; Ke Y; Shao B; Guo Y; Sun Y
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612101
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Clinicopathological features of NTRK3 gene rearrangement papillary thyroid carcinoma].
    Li HQ; Chen XY; Yu XB; Chen LY; Zhang X; Jin L; Wu ZZ; Chen Z
    Zhonghua Bing Li Xue Za Zhi; 2022 Feb; 51(2):126-131. PubMed ID: 35152631
    [No Abstract]   [Full Text] [Related]  

  • 67. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
    Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
    Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
    [No Abstract]   [Full Text] [Related]  

  • 68. The Genomic and Proteomic Profiles of NTRK Genes and Trk Receptors in Liver Hepatocellular Carcinoma.
    Wang H; Qi L; Zhong C; Fang X; Yuan Y
    Clin Med Insights Oncol; 2023; 17():11795549231180840. PubMed ID: 37456611
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
    Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B
    Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cytomorphologic features of NTRK-rearranged thyroid carcinoma.
    Viswanathan K; Chu YH; Faquin WC; Sadow PM
    Cancer Cytopathol; 2020 Nov; 128(11):812-827. PubMed ID: 33074583
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Nefarious NTRK oncogenic fusions in pediatric sarcomas: Too many to Trk.
    Aepala MR; Peiris MN; Jiang Z; Yang W; Meyer AN; Donoghue DJ
    Cytokine Growth Factor Rev; 2022 Dec; 68():93-106. PubMed ID: 36153202
    [TBL] [Abstract][Full Text] [Related]  

  • 72. CANTRK: A Canadian Ring Study to Optimize Detection of NTRK Gene Fusions by Next-Generation RNA Sequencing.
    Stockley TL; Lo B; Box A; Corredor AG; DeCoteau J; Desmeules P; Feilotter H; Grafodatskaya D; Greer W; Hawkins C; Huang WY; Izevbaye I; Lépine G; Martins Filho SN; Papadakis AI; Park PC; Riviere JB; Sheffield BS; Spatz A; Spriggs E; Tran-Thanh D; Yip S; Zhang T; Torlakovic E; Tsao MS
    J Mol Diagn; 2023 Mar; 25(3):168-174. PubMed ID: 36586421
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Clinicopathological characteristics of H3K27-altered diffuse midline glioma and evaluation of NTRK as its therapeutic target].
    Duan ZJ; Feng J; Yao K; Hu ZJ; Ma Z; Xiang L; Zhang XF; Qi XL
    Zhonghua Bing Li Xue Za Zhi; 2022 Nov; 51(11):1115-1122. PubMed ID: 36323540
    [No Abstract]   [Full Text] [Related]  

  • 74. NTRK fusion-positive colorectal cancer in Japanese population.
    Yonemaru J; Hashimoto T; Takayanagi D; Naka T; Yatabe Y; Kanemitsu Y; Shiraishi K; Sekine S
    Pathol Int; 2021 May; 71(5):355-359. PubMed ID: 33631044
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Non-secretory breast carcinomas lack NTRK rearrangements and TRK protein expression.
    Remoué A; Conan-Charlet V; Bourhis A; Flahec GL; Lambros L; Marcorelles P; Uguen A
    Pathol Int; 2019 Feb; 69(2):94-96. PubMed ID: 30707464
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma.
    Hung YP; Jo VY; Hornick JL
    Histopathology; 2019 Jul; 75(1):54-62. PubMed ID: 30801752
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Expanding the Spectrum of Adult NTRK3-Rearranged Spindle Cell Neoplasms: A Recurrent NTRK3-SQSTM1 Fusion Spindle Cell Tumor With Deceptively Bland Morphology.
    Punjabi LS; Sittampalam K
    Am J Clin Pathol; 2022 Apr; 157(4):485-493. PubMed ID: 34661642
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Biphasic squamoid alveolar papillary renal cell carcinoma: A unique papillary renal cell carcinoma with distinctive morphology, immunophenotype and molecular genetic features.
    Li Y; Wu X; Yang J; Jiang Y; Li Y; Zhang W; Yu W
    Pathol Res Pract; 2022 Nov; 239():154120. PubMed ID: 36201928
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinicopathological features and genomic profiles of a group of secretory breast carcinomas in which progressive cases have more complex genomic features.
    Lei T; Yang Y; Shi Y; Deng X; Peng Y; Wang H; Chen T
    Diagn Pathol; 2022 Dec; 17(1):101. PubMed ID: 36585729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.